Network Pharmacology,Integrated Bioinformatics,and Molecular Docking Reveals the Anti-Ovarian Cancer Molecular Mechanisms of Cinnamon ( Cinnamomum cassia (L.) J. Presl)

Abstract

Cinnamon (Cinnamomum cassia (L.) J. Presl) is a popular natural spice with various pharmacological properties. This study was based on network pharmacology integrating bioinformatics and molecular docking to explore the potential molecular mechanisms of cinnamon in the treatment of ovarian cancer (OC). The chemical composition of cinnamon was collected from the TCMSP database to predict its targets and construct a “cinnamon active component target” network. OC-related genes were retrieved from Genecards and DisGeNET databases. The “disease-target” network was established, and the drug targets were mapped to the disease targets, and the key targets obtained from the mapping were subjected to DAVID analysis to construct a “component-target-pathway” network diagram. The active ingredients of cinnamon were molecularly docked to the core targets to predict the molecular mechanism of cinnamon in the treatment of ovarian cancer. From cinnamon, 105 chemical components were screened and de-duplicated to obtain 15 active components and 74 drug target proteins, and 26 common targets were obtained after mapping drug targets to disease targets. 368 entries were identified by GO enrichment analysis, mainly including biological progresses such as regulation of smooth muscle contraction and regulation of tube diameter, and molecular functions such as antioxidant activity, and peroxidase activity. The KEGG pathway enrichment analysis identified 4 signaling pathways, neuroactive ligand-receptor interaction, HIF-1 signaling pathway, regulation of lipolysis in adipocytes, and complement and coagulation cascades. Molecular docking analysis showed good affinity of these key targets with representative components of OC. There was a stable interaction between DIBP and ADRB2 and NR3C1. There is a stable interaction between oleic acid and C2K, EDN1, ERBB2, PLAU, PLG, PRSS3, PTGS1, PTGS2, SERPINE1 and SLC2A1. Cinnamon exerted its therapeutic effects on OC through multiple pathways and targets.

Keywords

ovarian cancer network pharmacology molecular mechanism signaling pathway

Introduction

Ovarian cancer (OC) is a malignant tumor of the reproductive tract that poses a serious threat to women's lives.¹ In 2015, there were 52,100 new cases of ovarian cancer and 22,500 deaths in China.² Most OC patients are found to be advanced, and their susceptibility to extensive pelvic and abdominal metastases, multidrug resistance to primary or secondary chemotherapy, and recurrence has led to a high mortality rate, with the 5-year survival rate still hovering at 40%.^{3, 4} At present, the treatment of OC is usually a combination of surgery and chemotherapy,^{5, 6} but chemical drugs have a certain toxicity and sometimes resistance develops to them, and Chinese medicine has unique advantages in this regard.⁷ The vast majority of recurrent OC is incurable and treatment is mostly palliative with the aim of improving symptoms and quality of life, and so prevention of OC recurrence and reversal of platinum resistance are current clinical concerns.

Cinnamon is the dried bark of Cinnamomum cassia (L.) Presl, a plant of the Lauraceae family. Cinnamon is one of the most popular herbal ingredients in traditional oriental medicine and has a variety of pharmacological activities including antibacterial, anti-viral, and anticancer properties.⁸ Modern pharmacological studies have shown that cinnamon has various biological activities such as anti-cancer, anti-inflammatory, analgesic, anti-bacterial, hypoglycemic, cardiovascular protection, cytoprotective, neuroprotective and immunomodulatory.⁹ The chemical constituents of cinnamon have antitumor effects.¹⁰ Oleic acid-induced apoptosis in tumor cells was associated with either increased intracellular reactive oxygen species (ROS) production or cystein 3 activity.¹¹ Ingredients of cinnamon, including bingleyl acetate and caryophyllene oxide, were able to inhibit the growth of human ovarian cancer cell line A-2780.¹² Since 1963, cinnamon has been included in the Pharmacopoeia of the People's Republic of China, where more than 500 formulations containing cinnamon are used to treat various diseases such as cardiovascular, chronic gastrointestinal, gynecological, and inflammatory, as well as oxidative injury.^13–15 TP53, Akt1, and MYC are targets of Xiaoyaosan's anti-ovarian cancer therapy.¹⁶ TNF, MMP9, STAT3, PIK3CA, ERBB2, MTOR, IL2, PTGS2, KDR, and F2 are the targets of Epimedii's anti-ovarian cancer therapy.¹⁷ However, the mechanism of action of cinnamon in ovarian cancer is unclear.

In Chinese medicine research, analysis of the mechanism of active components for the treatment of diseases is a hot spot, but a difficult area. Network pharmacology provides a good platform for the study and analysis of multi-component, multi-target, and multi-pathway drugs.^{18, 19} The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) is a unique TCM systemic pharmacology platform from which relationships between drugs, target proteins, and diseases can be obtained.

In this study, network pharmacology integrated bioinformatics and molecular docking were applied to explore the potential targets and signaling pathways of cinnamon for the treatment of OC, and to predict the targets of the signaling pathways where cinnamon acts, with the aim of obtaining more detailed information on its mechanism for the treatment of OC.

Materials and Methods

Screening and Target Prediction of the Main Active Components of Cinnamon

The chemical composition of cinnamon was collected using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, https://old.tcmsp-e.com/tcmsp.php).²⁰ The TCSMP database was used to obtain all the main active components of cinnamon, and the database was used until 16th May, 2021. Two indicators, oral bioavailability (OB) ≥ 30% and drug-like index (DL) ≥ 0.08,²¹ were used as screening thresholds to determine the final drug active components. The potential target proteins corresponding to the active components were then collected one by one, and the protein names were normalized on the Uniprot database (https://www.uniprot.org/), and the species “Homo sapiens” was selected to obtain the potential targets corresponding to the drugs.

OC Disease-Related Target Acquisition　

OC-related genes were retrieved from GeneCards (https://www.genecards.org/)²² and DisGeNET databases (https://www.disgenet.org/) using the search term “ovarian cancer”, and OC-related targets were obtained by processing and removing duplicates from the collected disease targets.

Construction of a Protein–Protein Network

The potential targets of cinnamon in the treatment of OC were analyzed using STRING database (https://string-db.org/), and the corresponding species was set to “Homo sapiens”. To ensure the completeness and accuracy of the whole “PPI” network analysis process, the TSV format files were imported into Cytoscape 3.7.1 software and their interaction degree was analyzed by the plug-in CytoHubba. Candidate targets with node degrees above the average were selected.

Biofunctional and Pathway Enrichment Analysis　

The potential targets of cinnamon in the treatment of OC were enriched by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis using the human genome annotation database DAVID database (https://david.ncifcr f.gov/) to investigate the biological processes and signaling pathways involved in the treatment of OC with cinnamon. The identifier “GENE OFFICIAL SYMBOL” and the species “Homo sapiens” were selected and candidate targets were imported into DAVID 6.8.1 for GO entry and KEGG pathway annotation. The top ten biological processes (BP), cellular components (CC) and molecular function (MF) entries were plotted as histograms and the significantly different KEGG pathways were plotted as bubble plots using the R package at p < 0.05.

Network Construction and Analysis for OC　

Venn diagrams were used to analyze “ component-target” and “disease-target” and identify shared targets. The Venn diagram was drawn to obtain the targets of cinnamon in the treatment of OC by using the diagram to map “component-target” to “disease-target”. Cytoscape 3.7.1 software was used to construct a “drug active component-target” visual network.

Molecular Docking

Molecular docking relies on the “lock-and-key principle” of ligand-receptor interactions, simulating the interaction between small molecule ligands and receptor biomolecules.²³ The binding pattern and affinity between components and proteins can be predicted computationally.^{24, 25} All target proteins were obtained from the RCSB PDB database (http://www.rcsb.org/) as 3D structures. The entire molecular docking process was performed with the Molecular Operating Environment (MOE) (v2015.10), including 6 steps: 1. input protein PDB file; 2. protein structure protonation; 3. removal of water molecules; 4. protein structure energy minimization; 5. protein binding site analysis; 6. input ligand molecules, and molecular docking.

Results

the Main Active Components of Cinnamon

One hundred chemical components of Cinnamomum cassia were collected and collated. As shown in Table 1, OB ≥ 30% and DL ≥ 0.08 were used as criteria for screening and were combined with literature reports to identify the 15 main active components of cinnamon, which were EIC, α-cubebol, zoomaric acid, (Z)-caryophyllene, ()-aromadendrene, β-Cubebene, junipene, ()-sativene, hexadec-11-enal, T-muurolol, ()-ledene, (-)-caryophyllene oxide, DIBP, (-)-α-cedrene, and oleic acid.

Table 1.

Screening Results of Active Components of Cinnamon.

Mol ID	Molecule Name	MW	OB (%)	DL
MOL000131	EIC	280.5	41.9	0.14
MOL001599	α-cubebol	208.38	64.81	0.09
MOL001739	zoomaric acid	254.46	35.78	0.1
MOL000193	(Z)-caryophyllene	204.39	30.29	0.09
MOL000208	()-Aromadendrene	204.39	55.74	0.1
MOL000266	beta-Cubebene	204.39	32.81	0.11
MOL002697	junipene	204.39	44.07	0.11
MOL003522	()-Sativene	204.39	37.41	0.1
MOL003523	hexadec-11-enal	238.46	31.71	0.08
MOL003537	T-Muurolol	222.41	30.41	0.09
MOL003538	()-Ledene	204.39	51.84	0.1
MOL002003	(-)-Caryophyllene oxide	220.39	32.67	0.13
MOL000057	DIBP	278.38	49.63	0.13
MOL000612	(-)-alpha-cedrene	204.39	55.56	0.1
MOL000675	oleic acid	282.52	33.13	0.14

Constructing a Cinnamon Active Component Target Network

A total of 166 drug targets (no corresponding targets for hexadec-11-enal) were obtained by searching the 15 actives of cinnamon using TCMSP, and 74 active targets were obtained after de-duplication and standardization in the Uniprot database. The active components and active targets were imported into Cytoscape network visualization software to construct the active component-target network of cinnamon. As shown in Figure 1, there were 88 nodes (14 active components and 74 active targets) and 166 edges in the composition-target network, in which the red nodes represented the active components of cinnamon and the blue nodes represented the drug targets. As shown in Table S1, oleic acid in cinnamon can act on 48 targets. The highest degree of target action was found for muscarinic acetylcholine receptor M1 (CHRM1), which was associated with 11 chemical components, followed by γ-aminobutyric acid receptor subunit α-1 (GABRA1), which was associated with 10 chemical components.

Figure 1.

Component-target network of cinnamon.

Potential Targets of Cinnamon in the Treatment of OC

7255 OC-related targets were obtained from the Gene Cards database, as shown in Table S2. The DisGeNET database was used to obtain 2563 targets related to OC, as shown in Table S3. The 74 targets obtained from the drug prediction were mapped to the corresponding targets of the disease using Venn diagrams, resulting in 26 potential targets of cinnamon in OC, including ACHE, ADH1B, ADRA1A, ADRB2, BDNF, CAT, CCK, CRP, DPP4, EDN1, ERBB2, MPO, NR3C1, PGR, PLAU, PLG, PON1, PRSS3, PTGS1, PTGS2, SCD, SERPINE1, SLC2A1, SOAT1, SOD1, and TEP1, as shown in Figure 2.

Figure 2.

Screening of targets for OC treated by cinnamon.

Target PPI Network Analysis

As shown in Figure 3, the PPI network consisted of 26 targets of cinnamon for OC contained 26 nodes and 85 edges, with an average node degree of 6.54, an average local clustering coefficient of 0.534, an expected number of edges of 16, and a PPI concentration p-value of <1.0e-16. These 26 proteins may play a key role in the treatment of OC with cinnamon.

Figure 3.

Protein-protein interaction network of potential targets.

GO Functional Enrichment of key Targets of Cinnamon in the Treatment of OC Analysis

As shown in Table S4, 368 GO functional enrichment analyses were listed based on p < 0.05. As shown in Figure 4, the first 10 significant differences in BP were regulation of smooth muscle contraction, regulation of tube diameter, regulation of blood vessel size, regulation of blood vessel diameter, regulation of tube size, response to fatty acid, vascular process in circulatory system, regulation of blood pressure, aging, and response to nutrient levels (Figure 4). The top 10 significantly different CCs were caveola, plasma membrane raft, membrane raft, membrane microdomain, apical plasma membrane, secretory granule lumen, membrane region, blood microparticle, cytoplasmic vesicle lumen, and vesicle lumen (Figure 4). The top 10 significant differences in MF were antioxidant activity, peroxidase activity, oxidoreductase activity, acting on peroxide as acceptor, serine hydrolase activity, heme binding, tetrapyrrole binding, serine-type endopeptidase activity, serine-type peptidase activity, adrenergic receptor activity and steroid binding (Figure 4).

Figure 4.

Go and enrichment analysis of cinnamon for treating OC. The 26 potential targets of cinnamon in OC were imported into the DAVID database, and the key targets were analyzed for different biological processes at three levels: biological process (BP), cellular component (CC), and molecular function (MF).

KEGG Pathway Analysis of Cinnamon as a Target for OC Treatment

As shown in Figure 5 and Table S4, the KEGG pathway enrichment analysis of 26 key targets of cinnamon in OC identified four major signaling pathways, mainly related to neuroactive ligand-receptor interaction, HIF-1 signaling pathway, regulation of lipolysis in adipocytes, and complement and coagulation cascades.

Figure 5.

KEGG signaling pathway analysis of cinnamon for treating OC.

Construction of an “Active Component - Target - Pathway” Network for Cinnamon

Cytoscape software was used to model the “active ingredient - target - pathway” network of Cinnamon. The correlations between 9 components, 13 targets, and 4 pathways are shown in Figure 6. Oleic acid, a component of Cinnamon, regulates genes including CCK, EDN1, PLG, PRSS3, ERBB2, SERPINE1, SLC2A1, PTGS1, PTGS2, and PLAU of pathways including neuroactive ligand-receptor interaction, HIF-1 signaling pathway, regulation of lipolysis in adipocytes, and complement and coagulation cascades. PTGS2 was associated with EIC, zoomaric acid, (Z)-caryophyllene, β-cubebene, ()-sativene, (-)-caryophyllene oxide, (-)-α-cedrene, and oleic acid.

Figure 6.

Cinnamon active component-target-pathway network diagram. Cinnamon contains a complex network of effector components and targets, and between targets and pathways of action, where blue represents Cinnamon effector components, red represents component targets, and green represents pathways of action.

Molecular Docking Analysis

In our study, molecular docking was further applied to assess the interactions between components and targets, reducing the complexity and improving the accuracy of the composed target network. A virtual screen was performed using MOE to determine the binding affinity between protein models and 6 potentially active components obtained from component- component (including α-cedrene, caryophylene oxide, cubebene, DIBP, oleic acid, and sativene) target network. Twelve targets (ADRB2, CCK, EDN1, ERBB2, NR3C1, PLAU, PLG, PRSS3, PTGS1, PTGS2, SERPINE1, and SLC2A1) and 2 components (DIBP and oleic acid) were analyzed by molecular docking (Figure 7). There was a stable interaction between DIBP and ADRB2 and NR3C1. There is a stable interaction between oleic acid and C2K, EDN1, ERBB2, PLAU, PLG, PRSS3, PTGS1, PTGS2, SERPINE1 and SLC2A1. In conclusion, docking simulation studies showed that different binding models between components and proteins have different binding abilities. The detailed energy docking scores are in Table 2. The lower the score, the more stable the ligand-receptor binding. The calculated results show that representative components in cinnamon can bind well to the target genes.

Figure 7.

The docking model of components with 12 genes. Binding model of DIBP on the molecular surface of ADRB2 (A) and NR3C1 (E). The interaction model of DIBP with ADRB2 (a) and NR3C1 (e). Binding model of oleic acid on the molecular surface of (B) CCK, (C) EDN1, (D) ERBB2, (F) PLAU, (G) PLG, (H) PRSS3, (I) PTGS1, (J) PTGS2, (K) SERPINE1, and (L) SLC2A1. The interaction model of oleic acid with (b) CCK, (c) EDN1, (d) ERBB2, (f) PLAU, (g) PLG, (h) PRSS3, (i) PTGS1, (j) PTGS2, (k) SERPINE1, and (l) SLC2A1. The ligands in binding model and interaction model are colored in green and within the dashed line, respectively. The length of the bond was added to it.

Table 2.

Virtual Docking of 2 Representative Components of Cinnamon with OC Targets.

Compound	Binding energy / (kcal·mol-1)
Compound	ADRA1A	ADRB2	CCK	EDN1	ERBB2	NR3C1	PLAU	PLG	PRSS3	PTGS1	PTGS2	SERPINE1	SLC2A1
α-Cedrene	−3.588	−3.857	−3.242	−3.992	−3.902	−4.150	−4.167	−3.525	−4.054	−4.597	−4.021	−4.461	−4.998
Caryophylene Oxide	−3.693	−4.086	−3.197	−4.415	−3.702	−4.959	−3.865	−4.493	−4.336	−4.874	−4.915	−4.580	−5.272
Cubebene	−4.611	−4.705	−4.288	−5.751	−6.387	−6.614	−5.011	−5.688	−6.180	−5.755	−6.434	−6.603	−7.011
DIBP	−4.642	−4.556	−4.382	−5.003	−6.633	−6.176	−4.830	−5.476	−5.373	−5.361	−5.798	−5.596	−6.604
Oleic Acid	−5.009	−5.042	−5.288	−5.686	−6.473	−7.653	−5.312	−5.917	−5.567	−6.929	−6.570	−6.452	−7.802
Sativene	−4.344	−4.674	−4.029	−5.314	−6.131	−5.760	−4.926	−5.499	−4.950	−5.742	−6.160	−5.784	−6.720

Discussion

OC has an insidious clinical manifestation in the early stage, which makes diagnosis difficult. In the later stages, the disease progresses rapidly and is prone to extensive abdominal metastasis and chemotherapy multidrug resistance, and is prone to recurrence. Although surgical techniques are improving, chemotherapy regimens are becoming more standardized, and the side effects of new chemotherapeutic agents are diminishing, but there has been no significant improvement in the overall survival rate from ovarian cancer, which remains a major reproductive tract malignancy that poses a serious threat to women's lives.³

Herbs are gaining attention as effective and complementary anticancer therapeutic agents that can enhance the efficacy and reduce the toxicity of anticancer agents.²⁶ Oleic acid-induced apoptosis in tumor cells is associated with increased intracellular reactive oxygen species (ROS) production or cystein 3 activity.¹¹ Excess reactive species of oxygen and nitrogen may still cause oxidative damage to tissues and organs. Hesperidin, cinnamon, and Panax ginseng extracts all improved follicle development in three-dimensional cultures of mouse antral ovarian follicles.^{27, 28} Aqueous extract of cinnamon ameliorates oxidative damage to the ovaries of rats with polycystic ovary syndrome.¹⁵ Eugenol ameliorates tissue damage and oxidative stress after ovarian torsion/reversal in adult female rats.²⁹ FDY003, a combination of Artemisia capillaris (AcT), Chrysalis (Cm) and LjT, reduced the viability and increased the chemosensitivity of human OC cells.³⁰ In this study, the potential targets of cinnamon in the treatment of OC were predicted using network pharmacology, and the possible biological processes and signaling pathways involved in the treatment of OC with cinnamon were investigated to provide a reference and basis for further animal experiments and clinical trials on the treatment of OC with cinnamon. One hundred chemical components were searched for in cinnamon, with 15 components with DL ≥ 0.08 and OB ≥ 30%, presumably acting on OC-related signaling pathways via 74 target proteins. Oleic acid, an active component of cinnamon, can act on 48 targets. Targeting fatty acid oxidation (FAO) in HGSOC to promote antitumor activity and attenuate dissemination is a potential way to promote a more durable antitumor response and improve patient prognosis.³¹ Oleic acid stimulates HNOA cell survival by increasing glucose utilization.³² In this study, there was a stable interaction between DIBP and ADRB2 and NR3C1. There is a stable interaction between oleic acid and C2K, EDN1, ERBB2, PLAU, PLG, PRSS3, PTGS1, PTGS2, SERPINE1 and SLC2A1.

The analysis in this study identified four pathways through which cinnamon acts in relation to ovarian cancer, including neuroactive ligand-receptor interaction, HIF-1 signaling pathway, regulation of lipolysis in adipocytes, and complement and coagulation cascades. Dual drug-loaded micelles targeting the HIF and mTOR signaling pathways have been used in combination therapy for OC treatment.³³ Metformin prevents tumor-to-tumor crosstalk in OC by metabolically downregulating the expression of HIF1α in mesothelial cells.³⁴ Knockdown of HIF-1α promotes autophagy and inhibits the PI3K/AKT/mTOR signaling pathway in OC cells.³⁵ Pancreatic cancer (PC)-secreted exosomes cause lipolysis in subcutaneous adipose tissue.³⁶ There is a complex metabolic symbiosis between the adipocytes surrounding the tumor and the cancer cells, which stimulates their aggressiveness.³⁷ Complement and coagulation cascade pathways correlate with chemosensitivity and overall survival in patients with soft tissue sarcoma (STS).³⁸ The KEGG enrichment analysis showed that it was associated with neuroactive ligand-receptor interaction, regulation of lipolysis in adipocytes, and complement and coagulation cascades.

In this study, ADRA1A, ADRB2, CCK, EDN1, NR3C1, PLG, PRSS3, ERBB2, SERPINE1, SLC2A1, PTGS1, PTGS2, and PLAU were likely to be the therapeutic targets of cinnamon in the treatment of OC. Several factors related to stress and ovulation are differentially associated with ovarian tumors that respond to ADRB2 signaling.³⁹ The EDN1 axis promotes YAP-induced chemotherapy escape in OC.⁴⁰ Endothelin A receptor/β-arrestin signaling to the Wnt pathway makes ovarian cancer cells resistant to chemotherapy.⁴¹ Elevated PLG expression represents a good prognostic biomarker for advanced (FIGO III/IV) high grade serous ovarian cancer (HGSOC).⁴² Overexpression of PRSS3 can be used as a predictor of clinical prognosis in OC patients.⁴³ Silencing ERBB2 gene expression may inhibit activation of the MAPK1/MAPK3 signaling pathway, thereby suppressing the proliferation, invasion, and migration of OC cells.⁴⁴ FOXM1 and the EGFR/ERBB2 pathway are key points of treatment to disrupt the vulnerability of peritoneal spread and ovarian cancer cell adhesion.⁴⁵ ERBB2 reduces the drug sensitivity of OC cells by inducing stem cell-like properties.⁴⁶ Aberrant SERPINE1 DNA methylation is associated with carboplatin-induced epithelial-mesenchymal transition in epithelial ovarian cancer (EOC).⁴⁷ However, the role of genes including ADRA1A, CCK, NR3C1, SLC2A1, PTGS1, PTGS2, and PLAU in OC are not clear. The mechanism by which cinnamon acts through these targets in OC needs to be further investigated.

Modelling of the ‘active ingredient-target-pathway’ network of cinnamon using Cytoscape software showed correlations between 9 components, 13 targets, and 4 pathways (Figure 6). Subsequently, molecular docking simulations were performed for 9 components and 13 targets. A virtual screen using MOE determined the binding affinity between 13 proteins and 6 components including α-cedrene, caryophylene oxide, cubebene, DIBP, oleic acid, and sativene (Table 2). The molecular docking results for 12 target genes (ADRB2, CCK, EDN1, ERBB2, NR3C1, PLAU, PLG, PRSS3, PTGS1, PTGS2, SERPINE1, and SLC2A1) and two core components (DIBP and oleic acid) are shown in Figure 7. DIBP and oleic acid are expected to be potential drugs for the treatment of OC and will be the focus of future research.

Due to the limitations of network pharmacology and molecular docking, experiments need to be conducted in the future on the material basis, pharmacodynamics and pathway validation to provide a theoretical and experimental basis for the use of cinnamon in the treatment of OC.

Conclusion

This study showed that the main pathways involved in the treatment of OC by cinnamon are neuroactive ligand-receptor interaction, HIF-1 signaling pathway, regulation of lipolysis in adipocytes, and complement and coagulation cascades, and predicted that ADRA1A, ADRB2, CCK, EDN1, NR3C1, PLG, PRSS3, ERBB2, SERPINE1, SLC2A1, PTGS1, PTGS2, and PLAU may be potential targets of cinnamon for the treatment of OC.

Supplemental Material

sj-xlsx-1-npx-10.1177_1934578X221119118 - Supplemental material for Network Pharmacology, Integrated Bioinformatics, and Molecular Docking Reveals the Anti-Ovarian Cancer Molecular Mechanisms of Cinnamon (Cinnamomum cassia (L.) J. Presl)

Supplemental material, sj-xlsx-1-npx-10.1177_1934578X221119118 for Network Pharmacology, Integrated Bioinformatics, and Molecular Docking Reveals the Anti-Ovarian Cancer Molecular Mechanisms of Cinnamon (Cinnamomum cassia (L.) J. Presl) by Buze Chen, Xin Jin, Haihong Wang, Qingmei Zhou, Guilin Li and Xiaoyuan Lu in Natural Product Communications

Footnotes

Acknowledgements

This work was supported by Jiangsu Provincial Key Discipline of Maternal and Child Health (2017103033) and Xuzhou Key R&D Programme (ZYSB20210489).

Author Contributions

Buze Chen, Guilin Li, and Xiaoyuan Lu did the conception and design; Buze Chen, Guilin Li, and Xiaoyuan Lu did the acquisition; Buze Chen, Xin Jin, Haihong Wang, Qingmei Zhou, Guilin Li, and Xiaoyuan Lu did the analysis and interpretation of data; Buze Chen, Xin Jin, Guilin Li, and Xiaoyuan Lu did the drafting of the manuscript; Buze Chen, Xin Jin, Haihong Wang, Qingmei Zhou, Guilin Li, and Xiaoyuan Lu did the critical revision of the manuscript for important intellectual content; Buze Chen and Xiaoyuan Lu did the statistical analysis; Buze Chen and Xiaoyuan Lu did the obtaining funding; Buze Chen and Xiaoyuan Lu did the supervision.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Xuzhou Key R&D Programme, Jiangsu Provincial Key Discipline of Maternal and Child Health, (grant number ZYSB20210489, 2017103033).

Data Availability Statement

The data within the article are available from the corresponding author upon request.

ORCID iD

Buze Chen

Supplemental Material

Supplemental material for this article is available online.

References

Zhang

. Proteomics profiling of plasma exosomes in epithelial ovarian cancer: a potential role in the coagulation cascade, diagnosis and prognosis. Int J Oncol. 2019;54(5):1719-1733. doi:10.3892/ijo.2019.4742

Chen

Zheng

Baade

, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132. doi:10.3322/caac.21338

Mukhopadhyay

Bizzarri

Bradbury

Sinha

Bhaumik

Helm

. Metastatic involvement of lesser sac in advanced epithelial ovarian cancer. Int J Gynecol Cancer. Feb 2018;28(2):293-301. doi:10.1097/igc.0000000000001180

Runnebaum

Reichert

Ringsdorf

, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. J Cancer Res Clin Oncol. 2018;144(6):1185-1195. doi:10.1007/s00432-018-2637-1

Gupta

Naumann

. Ovarian cancer: screening and future directions. Int J Gynecol Cancer. 2019;29(1):195-200. doi:10.1136/ijgc-2018-000016

Gadducci

Guarneri

Peccatori

, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019;12(1):9. doi:10.1186/s13048-019-0484-6

Cortez

Tudrej

Kujawa

Lisowska

. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17-38. doi:10.1007/s00280-017-3501-8

Gao

Gou

Yuan

Ren

. Bioactivity-oriented purification of polyphenols from Cinnamomum cassia Presl. with anti-proliferation effects on colorectal cancer cells. Plant Foods Hum Nutr. 2020;75(4):561-568. doi:10.1007/s11130-020-00846-8

Zhang

Fan

, et al. Cinnamomum cassia Presl: a review of its traditional uses, phytochemistry, pharmacology and toxicology. Molecules. 2019;24(19):3473. doi:10.3390/molecules24193473

10.

Liu

Wan

Fan

Pei

. Targets and mechanism used by cinnamaldehyde, the main active ingredient in cinnamon, in the treatment of breast cancer. Front Pharmacol. 2020;11:582719-582719. doi:10.3389/fphar.2020.582719

11.

Carrillo

Cavia Mdel

Alonso-Torre

. Antitumor effect of oleic acid; mechanisms of action: a review. Nutr Hosp. 2012;27(6):1860-1865. doi:10.3305/nh.2012.27.6.6010

12.

Shahwar

Ullah

Khan

Ahmad

Saeed

Ullah

. Anticancer activity of Cinnamon tamala leaf constituents towards human ovarian cancer cells. Pak J Pharm Sci. 2015;28(3):969-972.

13.

Kwon

Kim

Jeong

, et al. Cortex cinnamomi extract prevents streptozotocin- and cytokine-induced beta-cell damage by inhibiting NF-kappaB. World J Gastroenterol. 2006;12(27):4331-4337. doi:10.3748/wjg.v12.i27.4331

14.

Hong

Yang

Kim

Eom

Lew

Kang

. Anti-inflammatory activity of cinnamon water extract in vivo and in vitro LPS-induced models. BMC Complement Altern Med. 2012;12:237. doi:10.1186/1472-6882-12-237

15.

Khodaeifar

Fazljou

SMB

Khaki

, et al. Investigating the role of hydroalcoholic extract of Apium graveolens and cinnamon zeylanicum on metabolically change and ovarian oxidative injury in a rat model of polycystic ovary syndrome. International Journal of Women’s Health and Reproduction Sciences. 2019;7(1):092-098. doi: 10.15296/ijwhr.2019.15

16.

Zhang

Yang

, et al. The mechanism of Xiaoyao San in the treatment of ovarian cancer by network pharmacology and the effect of stigmasterol on the PI3K/akt pathway. Dis Markers. 2021;2021:4304507. doi:10.1155/2021/4304507

17.

Wang

Gao

, et al. Study on the regulatory mechanism and experimental verification of icariin for the treatment of ovarian cancer based on network pharmacology. J Ethnopharmacol. 2020;262:113189. doi:10.1016/j.jep.2020.113189

18.

Zhang

Zhu

Bai

Ning

. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123. doi:10.3389/fphar.2019.00123

19.

Wei

Zhou

Niu

, et al. Network pharmacology exploration reveals the bioactive compounds and molecular mechanisms of Li-Ru-Kang against hyperplasia of mammary gland. Mol Genet Genomics. 2019;294(5):1159-1171. doi:10.1007/s00438-019-01569-5

20.

Wang

, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13. doi:10.1186/1758-2946-6-13

21.

Wang

Chen

J-H

Liu

Zhang

. Analysis of the active components and mechanism of three prescriptions in the treatment of COVID-19 via network pharmacology and molecular docking. Nat Prod Commun. 2021;16(9):1934578X2110477. doi:10.1177/1934578X211047702

22.

Piñero

Bravo

Queralt-Rosinach

, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833-d839. doi:10.1093/nar/gkw943

23.

Chaudhary

Mishra

. A review on molecular docking: novel tool for drug discovery. JSM Chemistry. 2016;4(3):1029.

24.

Friesner

Banks

Murphy

, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-1749. doi:10.1021/jm0306430

25.

Huang

Zhang

, et al. A network pharmacology-based strategy for predicting active ingredients and potential targets of LiuWei DiHuang pill in treating type 2 diabetes mellitus. Drug Des Devel Ther. 2019;13:3989-4005. doi:10.2147/dddt.s216644

26.

Wang

Sun

Wang

, et al. Efficacy and safety of Chinese Herbal Medicine on ovarian cancer after reduction surgery and adjuvant chemotherapy: a systematic review and meta-analysis. Front Oncol. 2019;9:730. doi:10.3389/fonc.2019.00730

27.

Shoorei

Banimohammad

Kebria

, et al. Hesperidin improves the follicular development in 3D culture of isolated preantral ovarian follicles of mice. Exp Biol Med (Maywood). 2019;244(5):352-361. doi:10.1177/1535370219831615

28.

Majdi Seghinsara

Shoorei

Hassanzadeh Taheri

, et al. Panax ginseng extract improves follicular development after mouse preantral follicle 3D culture. Cell J. 2019;21(2):210-219. doi:10.22074/cellj.2019.5733

29.

Barghi

Shokoohi

Khaki

Moghimian

Soltani

. Eugenol improves tissue damage and oxidative stress in adult female rats after ovarian torsion/detorsion. J Obstet Gynaecol. 2021;41(6):933-938. doi:10.1080/01443615.2020.1816938

30.

Lee

H-S

Lee

I-H

Kang

, et al. A network pharmacology study to uncover the mechanism of FDY003 for ovarian cancer treatment. Nat Prod Commun. 2022;17(2):1934578X2210754. doi:10.1177/1934578X221075432

31.

Sawyer

Qamar

Yamamoto

, et al. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Mol Cancer Res. 2020;18(7):1088-1098. doi:10.1158/1541-7786.mcr-19-1057

32.

Kuwata

Ohkubo

Kumamoto

, et al. Extracellular lipid metabolism influences the survival of ovarian cancer cells. Biochem Biophys Res Commun. 2013;439(2):280-284. doi:10.1016/j.bbrc.2013.08.041

33.

Doddapaneni

Al-Fatease

Rao

Alani

AWG

. Dual-drug loaded micelle for combinatorial therapy targeting HIF and mTOR signaling pathways for ovarian cancer treatment. J Control Release. 2019;307:272-281. doi:10.1016/j.jconrel.2019.06.036

34.

Hart

Kenny

Grassl

, et al. Mesothelial cell HIF1α expression is metabolically downregulated by metformin to prevent oncogenic tumor-stromal crosstalk. Cell Rep. 2019;29(12):4086-4098. doi:10.1016/j.celrep.2019.11.079. e6.

35.

Huang

Gao

, et al. Knockdown of hypoxia-inducible factor 1α (HIF-1α) promotes autophagy and inhibits phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway in ovarian cancer cells. Med Sci Monit. 2019;25:4250-4263. doi:10.12659/msm.915730

36.

Sagar

Sah

Javeed

, et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 2016;65(7):1165-1174. doi:10.1136/gutjnl-2014-308350

37.

Wang

Attané

Milhas

, et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI insight. 2017;2(4):e87489. doi:10.1172/jci.insight.87489

38.

Zhang

Chen

Zhao

, et al. Complement and coagulation cascades pathway correlates with chemosensitivity and overall survival in patients with soft tissue sarcoma. Eur J Pharmacol. 2020;879:173121. doi:10.1016/j.ejphar.2020.173121

39.

Huang

Tworoger

Hecht

, et al. Association of ovarian tumor β2-adrenergic receptor status with ovarian cancer risk factors and survival. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1587-1594. doi:10.1158/1055-9965.epi-16-0534

40.

Tocci

Cianfrocca

Sestito

, et al. Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Lett. 2020;492:84-95. doi:10.1016/j.canlet.2020.08.026

41.

Rosanò

Cianfrocca

Tocci

, et al. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 2014;74(24):7453-7464. doi:10.1158/0008-5472.can-13-3133

42.

Zhao

Dorn

Napieralski

, et al. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer. Biol Chem. 2017;398(7):765-773. doi:10.1515/hsz-2016-0282

43.

Cheng

Cui

Chang

. PRSS3 Expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2015;137(3):546-552. doi:10.1016/j.ygyno.2015.02.022

44.

Wang

Tong

. ERBB2 Gene expression silencing involved in ovarian cancer cell migration and invasion through mediating MAPK1/MAPK3 signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(10):5267-5280. doi:10.26355/eurrev_202005_21309

45.

Parashar

Nair

Geethadevi

, et al. Peritoneal spread of ovarian cancer harbors therapeutic vulnerabilities regulated by FOXM1 and EGFR/ERBB2 signaling. Cancer Res. 2020;80(24):5554-5568. doi:10.1158/0008-5472.can-19-3717

46.

Wang

Gao

Hai

Yang

Duan

. HER2 Decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way. Biosci Rep. 2019;39(3):BSR20180829. doi:10.1042/bsr20180829

47.

Pan

Wang

, et al. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296(6):1145-1152. doi:10.1007/s00404-017-4547-x

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.03 MB